CD79A and HIV-1 infection: These challenges, coupled with low Env-specific mucosal IgA levels during HIV-1 infection and after vaccination, have led to a poorly understood role of mucosal antibodies in defense against HIV-1, impeding our ability to determine whether mucosal responses need to be targeted by HIV-1 vaccine candidates.